Invitrogen Corporation Awarded Contract Extension For Biothreat Detection By U.S. Department Of Defense

CARLSBAD, Calif.--(BUSINESS WIRE)--Sept. 12, 2006--Invitrogen Corporation (Nasdaq:IVGN), a leading life science company providing innovative technologies to support disease research and drug discovery, today announced that its subsidiary, Invitrogen Federal Systems, was awarded a $1,243,000 extension to an existing contract with the U.S. Department of Defense. The contract will support research using Invitrogen's proprietary ProtoArray(TM) protein microarray technology to detect and analyze biothreat agents such as hemorrhagic fever viruses, poxviruses and Bacillus anthracis (anthrax). This research will build upon work conducted under the original Technical Assistance Agreement for $970,000 awarded in January 2006, which focused on the detection and analysis of smallpox and Yersinia pestis (plague).